Order Article Reprints

Stegelmeier AA, Santry LA, Guilleman MM, Matuszewska K, Minott JA, Yates JGE, Stevens BAY, Thomas SP, Vanderkamp S, Hanada K, et al. AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma. Biomedicines. 2022; 10(2):362. https://doi.org/10.3390/biomedicines10020362

Stegelmeier, Ashley A., Lisa A. Santry, Matthew M. Guilleman, Kathy Matuszewska, Jessica A. Minott, Jacob G. E. Yates, Brenna A. Y. Stevens, Sylvia P. Thomas, Sierra Vanderkamp, Kiersten Hanada, and et al. 2022. "AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma" Biomedicines 10, no. 2: 362. https://doi.org/10.3390/biomedicines10020362

Stegelmeier, A. A., Santry, L. A., Guilleman, M. M., Matuszewska, K., Minott, J. A., Yates, J. G. E., Stevens, B. A. Y., Thomas, S. P., Vanderkamp, S., Hanada, K., Pei, Y., Rghei, A. D., van Vloten, J. P., Pereira, M., Thompson, B., Major, P. P., Petrik, J. J., Bridle, B. W., & Wootton, S. K. (2022). AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma. Biomedicines, 10(2), 362. https://doi.org/10.3390/biomedicines10020362